AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 226 filers reported holding AMICUS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.62 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,883,136 | -18.7% | 730,521 | -16.0% | 0.01% | -15.4% |
| Q2 2023 | $10,925,052 | +38.1% | 869,829 | +21.9% | 0.01% | +30.0% |
| Q1 2023 | $7,911,550 | -10.3% | 713,395 | -1.2% | 0.01% | -16.7% |
| Q4 2022 | $8,819,454 | +53.1% | 722,314 | +30.9% | 0.01% | +50.0% |
| Q3 2022 | $5,759,091 | -0.7% | 551,637 | +2.1% | 0.01% | -46.7% |
| Q2 2022 | $5,801,000 | +481.8% | 540,107 | +413.0% | 0.02% | +650.0% |
| Q1 2022 | $997,000 | -78.7% | 105,282 | -74.0% | 0.00% | -77.8% |
| Q4 2021 | $4,676,000 | -37.4% | 404,890 | -48.2% | 0.01% | -40.0% |
| Q3 2021 | $7,469,000 | -6.2% | 782,015 | -5.3% | 0.02% | 0.0% |
| Q2 2021 | $7,960,000 | +10.6% | 825,754 | +13.4% | 0.02% | 0.0% |
| Q1 2021 | $7,195,000 | -54.4% | 728,241 | +6.5% | 0.02% | -53.1% |
| Q4 2020 | $15,794,000 | +10.9% | 683,987 | -32.2% | 0.03% | 0.0% |
| Q3 2020 | $14,240,000 | -15.5% | 1,008,544 | -9.8% | 0.03% | -17.9% |
| Q2 2020 | $16,861,000 | +30.4% | 1,118,106 | -20.1% | 0.04% | +11.4% |
| Q1 2020 | $12,931,000 | -11.5% | 1,399,463 | -6.7% | 0.04% | +16.7% |
| Q4 2019 | $14,605,000 | -20.2% | 1,499,432 | -34.3% | 0.03% | -25.0% |
| Q3 2019 | $18,301,000 | -18.5% | 2,281,797 | +26.8% | 0.04% | -16.7% |
| Q2 2019 | $22,462,000 | -12.9% | 1,799,833 | -5.1% | 0.05% | -17.2% |
| Q1 2019 | $25,787,000 | +67.3% | 1,896,094 | +17.8% | 0.06% | +52.6% |
| Q4 2018 | $15,417,000 | -24.8% | 1,609,308 | -5.1% | 0.04% | -9.5% |
| Q3 2018 | $20,509,000 | -1.5% | 1,696,320 | +27.2% | 0.04% | -4.5% |
| Q2 2018 | $20,829,000 | +0.4% | 1,333,496 | -3.3% | 0.04% | 0.0% |
| Q1 2018 | $20,743,000 | +18.6% | 1,379,176 | +13.5% | 0.04% | +22.2% |
| Q4 2017 | $17,487,000 | +1423.3% | 1,215,239 | +1496.5% | 0.04% | +1700.0% |
| Q3 2017 | $1,148,000 | +72.6% | 76,119 | +15.2% | 0.00% | +100.0% |
| Q2 2017 | $665,000 | +72.3% | 66,073 | +22.2% | 0.00% | 0.0% |
| Q1 2017 | $386,000 | -95.3% | 54,082 | -96.7% | 0.00% | -95.0% |
| Q4 2016 | $8,222,000 | -32.2% | 1,654,522 | +1.0% | 0.02% | -13.0% |
| Q3 2016 | $12,125,000 | +16.3% | 1,638,471 | -14.2% | 0.02% | -11.5% |
| Q2 2016 | $10,430,000 | -8.2% | 1,910,196 | +42.0% | 0.03% | -7.1% |
| Q1 2016 | $11,367,000 | +34.1% | 1,345,146 | +53.9% | 0.03% | +33.3% |
| Q4 2015 | $8,477,000 | +203.1% | 873,861 | +337.1% | 0.02% | +200.0% |
| Q3 2015 | $2,797,000 | +322.5% | 199,911 | +327.1% | 0.01% | +250.0% |
| Q2 2015 | $662,000 | – | 46,811 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |